PDF(Pubmed)
Abstract：
UNASSIGNED: To determine the optimal letrozole regimen for ovulation induction (OI) in women with polycystic ovary syndrome (PCOS).
UNASSIGNED: Retrospective cohort study.
UNASSIGNED: Single academic fertility clinic from 2015-2022.
UNASSIGNED: A total of 189 OI cycles in 52 patients with PCOS.
UNASSIGNED: Patients were prescribed 1 of 4 letrozole regimens (group 1: 2.5 mg for 5 days, group 2: 2.5 mg for 10 days, group 3: 5 mg for 5 days, and group 4: 5 mg for 10 days).
UNASSIGNED: The primary outcome was ovulation, and secondary outcomes included multifollicular development, and clinical pregnancy rate, which were analyzed with binary logistic regression. Kaplan-Meier cumulative response curves and a Cox proportional hazard regression model were used for time-dependent analyses.
UNASSIGNED: Mean age was 30.9 years (standard deviation [SD], 3.6) and body mass index was 32.1 kg/m2 (SD, 4.0). Group 2 (odds ratio [OR], 9.12; 95% confidence interval [CI], 1.92-43.25), group 3 (OR, 3.40; 95% CI, 1.57-7.37), and group 4 (OR, 5.94; 95% CI, 2.48-14.23) had improved ovulation rates after the starting regimen as compared with group 1. Cumulative ovulation rates exceeded 84% in all groups, yet those who received 5 mg and/or 10 days achieved ovulation significantly sooner. Multifollicular development was not increased in groups 2-4 as compared with group 1. Groups 2-4 also demonstrated improved time to pregnancy.
UNASSIGNED: Ovulation rates are improved when starting with letrozole at 5 mg and/or a 10-day extended course as compared with the frequently-used 2.5 mg for 5 days. This may shorten time to ovulation and pregnancy.
UNASSIGNED: Retrospective cohort study.
UNASSIGNED: Single academic fertility clinic from 2015-2022.
UNASSIGNED: A total of 189 OI cycles in 52 patients with PCOS.
UNASSIGNED: Patients were prescribed 1 of 4 letrozole regimens (group 1: 2.5 mg for 5 days, group 2: 2.5 mg for 10 days, group 3: 5 mg for 5 days, and group 4: 5 mg for 10 days).
UNASSIGNED: The primary outcome was ovulation, and secondary outcomes included multifollicular development, and clinical pregnancy rate, which were analyzed with binary logistic regression. Kaplan-Meier cumulative response curves and a Cox proportional hazard regression model were used for time-dependent analyses.
UNASSIGNED: Mean age was 30.9 years (standard deviation [SD], 3.6) and body mass index was 32.1 kg/m2 (SD, 4.0). Group 2 (odds ratio [OR], 9.12; 95% confidence interval [CI], 1.92-43.25), group 3 (OR, 3.40; 95% CI, 1.57-7.37), and group 4 (OR, 5.94; 95% CI, 2.48-14.23) had improved ovulation rates after the starting regimen as compared with group 1. Cumulative ovulation rates exceeded 84% in all groups, yet those who received 5 mg and/or 10 days achieved ovulation significantly sooner. Multifollicular development was not increased in groups 2-4 as compared with group 1. Groups 2-4 also demonstrated improved time to pregnancy.
UNASSIGNED: Ovulation rates are improved when starting with letrozole at 5 mg and/or a 10-day extended course as compared with the frequently-used 2.5 mg for 5 days. This may shorten time to ovulation and pregnancy.
摘要：
■确定多囊卵巢综合征（PCOS）女性排卵诱导（OI）的最佳来曲唑方案。
■回顾性队列研究。
■2015-2022年的单一学术生育诊所。
■52例PCOS患者共189个OI周期。
■患者接受了4种来曲唑方案中的1种（第1组：2.5mg，持续5天，第2组：2.5毫克，持续10天，第3组：5毫克，持续5天，和第4组：5毫克，持续10天）。
■主要结果是排卵，次要结局包括多卵泡发育，和临床妊娠率，用二元Logistic回归分析。Kaplan-Meier累积反应曲线和Cox比例风险回归模型用于时间依赖性分析。
■平均年龄为30.9岁（标准偏差[SD]，3.6），体重指数为32.1kg/m2（SD，4.0).第2组(赔率比[OR]，9.12；95%置信区间[CI]，1.92-43.25),第3组(OR,3.40；95%CI，1.57-7.37），和第4组(或，5.94；95％CI，2.48-14.23）与第1组相比，开始方案后排卵率提高。所有组的累积排卵率都超过84%，然而,接受5mg和/或10天的患者排卵明显更早.与第1组相比，第2-4组的多卵泡发育没有增加。第2-4组也表现出改善的妊娠时间。
■与经常使用的2.5mg持续5天相比，以5mg和/或10天的延长疗程开始时，排卵率得到改善。这可能会缩短排卵和怀孕的时间。
■回顾性队列研究。
■2015-2022年的单一学术生育诊所。
■52例PCOS患者共189个OI周期。
■患者接受了4种来曲唑方案中的1种（第1组：2.5mg，持续5天，第2组：2.5毫克，持续10天，第3组：5毫克，持续5天，和第4组：5毫克，持续10天）。
■主要结果是排卵，次要结局包括多卵泡发育，和临床妊娠率，用二元Logistic回归分析。Kaplan-Meier累积反应曲线和Cox比例风险回归模型用于时间依赖性分析。
■平均年龄为30.9岁（标准偏差[SD]，3.6），体重指数为32.1kg/m2（SD，4.0).第2组(赔率比[OR]，9.12；95%置信区间[CI]，1.92-43.25),第3组(OR,3.40；95%CI，1.57-7.37），和第4组(或，5.94；95％CI，2.48-14.23）与第1组相比，开始方案后排卵率提高。所有组的累积排卵率都超过84%，然而,接受5mg和/或10天的患者排卵明显更早.与第1组相比，第2-4组的多卵泡发育没有增加。第2-4组也表现出改善的妊娠时间。
■与经常使用的2.5mg持续5天相比，以5mg和/或10天的延长疗程开始时，排卵率得到改善。这可能会缩短排卵和怀孕的时间。
